HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Searches for "manjaro drug" almost always mean Mounjaro (tirzepatide, Eli Lilly). This is a brief disambiguation post that explains what Mounjaro is, what it's FDA-approved for, and where to go from here.

What Mounjaro actually is

Mounjaro is a GIP and GLP-1 dual receptor agonist marketed by Eli Lilly. It is FDA-approved for type 2 diabetes (FDA-approved 2022). Mounjaro is administered as a once-weekly subcutaneous injection per its FDA label. Per-month list price as of April 2026 is approximately $1,069 per month at U.S. list price as of April 2026 (Eli Lilly published pricing).

Key facts about Mounjaro

  • Active ingredient: tirzepatide
  • Manufacturer: Eli Lilly
  • FDA-approved indication: type 2 diabetes (FDA-approved 2022)
  • Format: once-weekly subcutaneous injection
  • List price (April 2026): approximately $1,069 per month at U.S. list price as of April 2026 (Eli Lilly published pricing)

Where this leaves you

If you were searching for Mounjaro: it is a real, FDA-approved GIP and GLP-1 dual receptor agonist available by prescription. The PlexusDx Weight Management Protocols collection includes the active ingredient (tirzepatide) through clinician-supervised compounded protocols. To start upstream with the genetic context, the Precision Peptide Genetic Test analyzes the GLP-1 pathway biology that sits underneath any of these decisions.

Upstream of any GLP-1 protocol decision, the PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape baseline GLP-1, appetite-regulation, and energy-balance biology. That genetic context is the test before you invest framing PlexusDx applies to every protocol conversation.

Related reading on PlexusDx: GLP-1 Hormone, What Is GLP-1?, What Is GLP-1?, GLP-1 Receptor Agonist.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Learn more about the PlexusDx Tirzepatide protocol or the oral tirzepatide protocol inside the Weight Management Protocols collection. To start upstream with the genetic context, take the Precision Peptide Genetic Test first.

Frequently Asked Questions

Is "manjaro drug" the same as Mounjaro?

Yes — "manjaro drug" is a common misspelling or phonetic search variant of Mounjaro (tirzepatide, Eli Lilly). It is the same medication. Mounjaro is FDA-approved for type 2 diabetes (FDA-approved 2022) and is administered as a once-weekly subcutaneous injection.

How is Mounjaro actually spelled?

Mounjaro is the brand name; the active ingredient is tirzepatide, marketed by Eli Lilly. Confusion with the spelling is common because the name is unusual. The FDA label and manufacturer materials use the spelling "Mounjaro".

Where can I learn more about Mounjaro?

The Eli Lilly product website and the FDA label are the primary sources. The PlexusDx Education Hub also has explainer content on the GLP-1 receptor agonist class — including the tirzepatide active ingredient and the genetic pathways that underlie all GLP-1 protocol decisions.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.